Shuang G Zhao, Jamie M Sperger, Jennifer L Schehr, Rana R McKay, Hamid Emamekhoo, Anupama Singh, Zachery D Schultz, Rory M Bade, Charlotte N Stahlfeld, Cole S Gilsdorf, Camila I Hernandez, Serena K Wolfe, Richel D Mayberry, Hannah M Krause, Matt Bootsma, Kyle T Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos E Kyriakopoulos, David Kosoff, Xiao X Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul M Harari, Wei Huang, Himisha Beltran, Toni K Choueiri, Howard I Scher, Dana E Rathkopf, Susan Halabi, Andrew J Armstrong, David J Beebe, Menggang Yu, Kaitlin E Sundling, Mary-Ellen Taplin, Joshua M Lang
BackgroundNeuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.MethodsWe performed analytical validation of a Circulating Tumor Cell (CTC) multiplex RNA qPCR assay to identify the limit of quantification (LOQ) in cell lines, synthetic cDNA, and patient samples. We next profiled 116 longitudinal samples from a prospectively collected institutional cohort of 17 patients with metastatic prostate cancer (7 NEPC, 10 adenocarcinoma) as well as 265 samples from 139 patients enrolled in 3 adenocarcinoma phase II trials of androgen receptor signaling inhibitors (ARSIs)...
November 1, 2022: Journal of Clinical Investigation